{"name":"Citryll BV","slug":"citryll-bv","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"CIT-013 medium dose","genericName":"CIT-013 medium dose","slug":"cit-013-medium-dose","indication":"Phase 2 clinical trial for unspecified indication","status":"phase_2"},{"name":"CIT-013 low dose","genericName":"CIT-013 low dose","slug":"cit-013-low-dose","indication":"Other","status":"phase_2"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"CIT-013 high dose","genericName":"CIT-013 high dose","slug":"cit-013-high-dose","indication":"Type 2 diabetes","status":"phase_2"}]}],"pipeline":[{"name":"CIT-013 medium dose","genericName":"CIT-013 medium dose","slug":"cit-013-medium-dose","phase":"phase_2","mechanism":"CIT-013 is a medium dose of a drug that targets a specific molecular pathway.","indications":["Phase 2 clinical trial for unspecified indication"],"catalyst":""},{"name":"CIT-013 high dose","genericName":"CIT-013 high dose","slug":"cit-013-high-dose","phase":"phase_2","mechanism":"CIT-013 high dose is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"CIT-013 low dose","genericName":"CIT-013 low dose","slug":"cit-013-low-dose","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxOaVM4UVVCVnlGMTdLRHpYSGltN2NaenJWazB4Q3B3ZGRHSi1JQUN6Z25nUUFKTlowdXZwRlQ4SFE2NWFDM0tIdExCRzhSWF9hMnZPampJWEVFZWdSU1JYWjRPZThLNTNZUkp0MkhKR2xRelRWQjh2SUxSdFdwVmJiQWxzbzFXeVdEYkRZRDJBUWpJY1FLWW9OR2lqNWRsUQ?oc=5","date":"2023-06-14","type":"pipeline","source":"EU-Startups","summary":"74 Top Biotechnology Startups and Companies in The Netherlands (2021) - EU-Startups","headline":"74 Top Biotechnology Startups and Companies in The Netherlands (2021) - EU","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_2":3},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}